Cerebral Small Vessel Diseases Clinical Trial
Official title:
Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease
This study was a multicenter, prospective, randomized controlled trial. In this study, 510 patients with cognitive impairment of cerebral small vessel disease who met the inclusion criteria are randomly included in multiple centers and randomized into two groups (standard treatment group and mouse nerve growth factor addition treatment group). The standard treatment group is treated with conventional drugs and cholinesterase inhibitors. In addition to the above treatment, the mouse nerve growth factor addition treatment group is administered with nerve growth factor 20 μg (9000 U)/vial for 14 consecutive days, intramuscularly once a day. Systematic clinical evaluation of patient cognitive function is performed at baseline, 14-day, and 3-month follow-up, and imaging (MR) is also evaluated twice at baseline, 14-day, and 3-month follow-up. At last observe the clinical effect of mouse nerve growth factor on cognitive impairment of cerebral small vessel disease.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | February 28, 2021 |
Est. primary completion date | November 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Aged 50-80 years old; 2. Clinical symptoms of acute CSVD, including Transient ischemic attack (TIA) or lacunar infarction, and with related lesions on MRI imaging (acute infarction with diameter < 20mm on (diffusion weighted imaging) DWI or with diameter of 3-15mm on MRI-T1,T2 or FLAIR); 3. For patients with chronic CSVD symptoms, two or more CSVD imaging markers are required : lacune (number > = 1), white matter lesion (Fazekas > = 2), cerebral microbleeds (number > =1 in deep white matter), enlarged perivascular space(number > = 10 in basal ganglia); 4. Clinical diagnosis of vascular cognitive impairment or dementia, MMSE score =<26; 5. Signed informed consent. Exclusion Criteria: 1. Intracranial or extracranial arterial stenosis of > 50% luminal stenosis or prior history of endarterectomy of cerebral large arteries; 2. TOAST classification suggested (very) possible cardioembolic stroke; 3. Large cortical or subcortical infarction with diameter > 1.5cm on MRI; White matter lesions caused by other diseases such as multiple sclerosis; Other central nervous system diseases such as cerebral hemorrhage, brain trauma, epilepsy, encephalitis, hydrocephalus or brain tumors; Oher systemic diseases, such as liver and kidney insufficiency, tumor, etc.; 4. History of alcohol intoxication, drug addiction, or mental disease, or severe aphasia; 5. Contraindication for MRI examination. - |
Country | Name | City | State |
---|---|---|---|
China | Zhujiang Hospiatal | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Zhujiang Hospital | Dongguan People's Hospital, First Affiliated Hospital of Jinan University, First Affiliated Hospital of Shantou University Medical College, First Affiliated Hospital, Sun Yat-Sen University, Guangdong 999 Brain Hospital, Houjie Hospital of Dongguan City, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The First Affiliated Hospital of Guangdong Pharmaceutical University, Wuhan University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change of Alzheimer's disease assessment scale-cognition (ADAS-cog) score | Cognitive function assessment | Baseline -14 days -3 months | |
Secondary | change of Mini-mental State Examination (MMSE) | Dementia screening scale | Baseline -14 days -3 months | |
Secondary | Montreal Cognitive Assessment (MoCA) scale | A rapid screening tool for mild cognitive impairment | Baseline -14 days -3 months | |
Secondary | digit span test | test the ability to concentrate attention, instantaneous memory and anti - information interference ability | Baseline -14 days -3 months | |
Secondary | Activity of Daily Living Scale | Barthel index was used to reflect the daily life ability of the interviewees | Baseline -14 days -3 months | |
Secondary | Patient Health Questionnaire-9 Score | Depression assessment tool | Baseline -14 days -3 months | |
Secondary | Hamilton anxiety scale | Assess the severity of anxiety symptoms in neurosis and other patients | Baseline -14 days -3 months | |
Secondary | Hamilton depression scale | A commonly used scale in clinical evaluation of depression | Baseline -14 days -3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04109963 -
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
|
Phase 2 | |
Not yet recruiting |
NCT06416371 -
Retinal Vessel Leakage in Cerebral Small Vessel Disease
|
||
Not yet recruiting |
NCT05967728 -
Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care
|
Phase 2 | |
Completed |
NCT05714813 -
Circuit Training and Retina
|
N/A | |
Not yet recruiting |
NCT06077305 -
A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
|
||
Not yet recruiting |
NCT06061692 -
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD)
|
Phase 4 | |
Recruiting |
NCT04962295 -
China Imaging-based Biobank of Cerebral Small Vessal Diseases
|
||
Completed |
NCT02801032 -
Effect of Tadalafil on Cerebral Large Arteries in Stroke
|
Phase 2 | |
Not yet recruiting |
NCT05594966 -
Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
|
||
Terminated |
NCT02890888 -
Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease
|
N/A | |
Recruiting |
NCT04318119 -
Cerebral Small Vessel Disease Registry Study
|
||
Recruiting |
NCT03906123 -
The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia
|
N/A | |
Recruiting |
NCT05306834 -
Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease
|
N/A | |
Not yet recruiting |
NCT05583266 -
Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)
|
Phase 4 | |
Recruiting |
NCT05173896 -
Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial
|
Phase 2 | |
Recruiting |
NCT01819441 -
Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients
|
Phase 4 | |
Recruiting |
NCT01688505 -
Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function
|
N/A | |
Recruiting |
NCT04330222 -
Cambridge 7 Tesla Cerebral Small Vessel Disease Study
|
||
Recruiting |
NCT04298866 -
White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI
|
N/A | |
Not yet recruiting |
NCT06301711 -
Investigation of Potential Mechanisms in Stellate Ganglion Block in Individuals With Cerebral Small Vessel Disease
|
N/A |